Compare Invesco NASDAQ 100 ETF (QQQM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Invesco NASDAQ 100 ETF trades at $296.39 (market cap $111.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 14.9× Spyre Therapeutics Inc. Common Stock's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 56 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QQQM | SYRE | |
|---|---|---|
Market Cap | $111.77B | $7.52B |
Volume | 2,346,098 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $108.92 |
52-Week Low | $229.87 | $22.18 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $306.18, down 0.33% with a bullish technical signal from moving averages. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads may offset this benefit. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show neutral oscillators with key support at $304-$306 and resistance at $308-$310.
QQQM offers exposure to Nasdaq-100 growth stocks with competitive fees, but faces competition from alternatives like SCHG and QQQE. The ETF's performance depends on technology sector leadership, with concentration risk in top holdings. Recent news highlights tax implications of similar ETFs, emphasizing the importance of understanding distribution characteristics for long-term returns.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
